Q-omics provides the consensus-scored ENKUR profile across patient tissues and cancer cell-line models. ENKUR expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ENKUR is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ENKUR RNA expression shows 17,428 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, KIRC, and TGCT as cancer lineages where ENKUR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENKUR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENKUR survival associations across molecular data types. ENKUR RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENKUR RNA expression–survival associations across cancer types. High ENKUR expression shows unfavorable associations in SCLC, BLCA and KIRP, but favorable associations in READ, UCEC and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for ENKUR RNA expression.
This table summarizes ENKUR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ENKUR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENKUR shows lower tumor expression in KICH, LUSC, THCA and LUAD and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher ENKUR RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p < 0.001).
This table shows molecular features associated with ENKUR in patient tissues and cancer cell lines. In patient samples, ENKUR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ENKUR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
